Answer
Viral load should be monitored closely during pregnancy in patients taking Emtricitabine/Rilpivirine/Tenofovir Alafenamide Gilead because rilpivirine exposure is lower during pregnancy, and similarly low exposure in Phase 3 studies was associated with increased risk of virological failure.
Sources for this answer
- Emtricitabine/Rilpivirine/Tenofovir Alafenamide Gilead 200 mg/25 mg/25 mg film-coated tabletsGilead Sciences Ltd · emc · SmPC §4.4 Special warnings and precautions for use · Version 24Document updated
Sources checked